Cargando…

Vertebral compression fracture after stereotactic ablative radiotherapy in patients with oligometastatic bone lesions from hepatocellular carcinoma

BACKGROUND AND PURPOSE: Stereotactic ablative radiotherapy (SABR) is popularly used to treat bone metastasis. Despite its efficacy, adverse events, including vertebral compression fracture (VCF), are frequently observed. Here, we investigated VCF risk after SABR for oligometastatic vertebral bone me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hyung Kim, Tae, Kim, Jina, Lee, Joongyo, Nam, Taek-Keun, Min Choi, Young, Seong, Jinsil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195846/ https://www.ncbi.nlm.nih.gov/pubmed/37216046 http://dx.doi.org/10.1016/j.ctro.2023.100636

Ejemplares similares

Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 20-04)
por: Kim, Tae Hyung, et al.
Publicado: (2022)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Skull Base Metastasis from Hepatocellular Carcinoma: Clinical Presentation and Efficacy of Radiotherapy
por: Kim, Kangpyo, et al.
Publicado: (2022)

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients
por: Morales-Orue, Ignacio, et al.
Publicado: (2020)

CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
por: Kataria, Tejinder, et al.
Publicado: (2021)

Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis
por: Kim, Kangpyo, et al.
Publicado: (2021)

Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma
por: Webking, Samantha, et al.
Publicado: (2023)

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC
por: Badellino, Serena, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy for spinal metastasis from hepatocellular carcinoma: its oncologic outcomes and risk of vertebral compression fracture
por: Yoo, Gyu Sang, et al.
Publicado: (2017)

Stereotactic body radiation therapy and radiofrequency ablation in patients with hepatocellular carcinoma: not a rival but a partner for the cure
por: Kim, Nalee, et al.
Publicado: (2022)

Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma?
por: Choi, Seo Hee, et al.
Publicado: (2018)

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?
por: Al-Shafa, Faiez, et al.
Publicado: (2019)

Stereotactic ablative body radiotherapy for oligometastatic inguinal lymph node in castrate resistant prostate cancer
por: Goyal, Shikha, et al.
Publicado: (2023)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
por: Kim, Yong Tae, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care
por: Raymakers, Adam J. N., et al.
Publicado: (2021)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
por: Mazzola, Rosario, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
por: Feng, Xiao-Yao, et al.
Publicado: (2022)

Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma
por: Kim, Jun Won, et al.
Publicado: (2016)

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
por: Comito, Tiziana, et al.
Publicado: (2014)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy
por: O'Cathail, Sean M., et al.
Publicado: (2020)

Long‐term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer
por: Wijetunga, N. Ari, et al.
Publicado: (2021)

Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients
por: Ma, Ming-Wei, et al.
Publicado: (2022)

Effect of histology on stereotactic body radiotherapy for non-small cell lung cancer oligometastatic pulmonary lesions
por: Allen, Alexander J., et al.
Publicado: (2023)

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
por: Franceschini, Davide, et al.
Publicado: (2021)

Stereotactic Radiotherapy in the Treatment of Paraneoplastic Vasculitis in Oligometastatic Renal Cell Carcinoma
por: Burgess, Laura, et al.
Publicado: (2021)

Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma
por: Paik, Eun Kyung, et al.
Publicado: (2016)

The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms
por: Dahele, Max, et al.
Publicado: (2011)

Peripheral blood lymphocyte changes after stereotactic ablative body radiotherapy to lung or liver metastases in patients with oligometastatic cancers
por: Novikov, Sergey Nikolaevich, et al.
Publicado: (2023)

Case report: L5 tomita En bloc spondylectomy for oligometastatic liposarcoma with post adjuvant stereotactic ablative radiotherapy
por: Saha, Priyanshu, et al.
Publicado: (2023)

Efficacy of Liver-Directed Combined Radiotherapy in Locally Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Kim, Jina, et al.
Publicado: (2023)

Hepatocellular Carcinoma in the COVID‐19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?
por: Scorsetti, Marta, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
por: Palma, David A, et al.
Publicado: (2012)

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
por: Palma, David A., et al.
Publicado: (2020)

Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments
por: Navarria, Pierina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_it59vr5bemvs5ugc75bic934m8